These findings collectively reinforce the concept that SF-AR exerts its anti-HCC activity through the concerted engagement of multiple bioactive constituents with several nodes of the inflammatory cascade, rather than relying on a single dominant compound–target pair. The gene discussed is AR; the disease is hepatocellular carcinoma.